(Health-NewsWire.Net, October 28, 2016 ) Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression.
There are currently 203 products in active development, excluding four with an unknown stage of development. Although many of the targets identified in the pipeline are well established in the management of COPD, there are some novel, first-in-class targets. This reflects the growing understanding of the underlying mechanisms that characterize the disease.
Scope
The COPD market has benefited from notable additions over recent years.
Which classes of drug dominate the market? What additional benefits have newly approved therapies brought to market? How do the leading marketed therapies compare clinically? The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies. Which molecular targets appear most frequently in the pipeline? How will the new therapies be positioned in the treatment of COPD? How have selected late-stage pipeline therapies performed in clinical trials? COPD clinical trials have an overall attrition rate of 89.6%. What are the failure rates for individual Phases of clinical development?